JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.

Autor: Bonneux B; Laboratory for Microbiology, Parasitology and Hygiene, University of Antwerp, Universiteitsbaan 1, 2610 Wilrijk, Belgium; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Shareef A; Department of Virology, Immunology & Microbiology, National Emerging Infectious Diseases Laboratories, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA., Tcherniuk S; Unité de Virologie et Immunologie Moléculaires (VIM, UMR892), INRAE, Université Paris-Saclay, 78352 Jouy-en-Josas, France., Anson B; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., de Bruyn S; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Verheyen N; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Thys K; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Conceição-Neto N; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Van Ginderen M; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Kwanten L; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Ysebaert N; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Vranckx L; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Peeters E; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Lanckacker E; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Gallup JM; Iowa State University, Ames, IA 50011, USA., Sitthicharoenchai P; Iowa State University, Ames, IA 50011, USA., Alnajjar S; Iowa State University, Ames, IA 50011, USA., Ackermann MR; Iowa State University, Ames, IA 50011, USA., Adhikary S; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Bhaumik A; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Patrick A; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Fung A; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Sutto-Ortiz P; AFMB, Aix-Marseille University, CNRS UMR 7257, 163 Avenue de Luminy, Marseille, France., Decroly E; AFMB, Aix-Marseille University, CNRS UMR 7257, 163 Avenue de Luminy, Marseille, France., Mason SW; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Lançois D; Janssen France, 27106 Val de Reuil, France., Deval J; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Jin Z; Janssen Research & Development LLC, Spring House (PA 19477) And Brisbane (CA 94005), USA., Eléouët JF; Unité de Virologie et Immunologie Moléculaires (VIM, UMR892), INRAE, Université Paris-Saclay, 78352 Jouy-en-Josas, France., Fearns R; Department of Virology, Immunology & Microbiology, National Emerging Infectious Diseases Laboratories, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA., Koul A; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. Electronic address: akoul@its.jnj.com., Roymans D; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Rigaux P; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Herschke F; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. Electronic address: fherschk@its.jnj.com.

Publikováno v: Antiviral research [Antiviral Res] 2024 Jul; Vol. 227, pp. 105907. Date of Electronic Publication: 2024 May 19.

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

Autor: Dierynck I; Tibotec BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium. idierinc@its.jnj.com, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2011 Dec; Vol. 55 (12), pp. 5723-31. Date of Electronic Publication: 2011 Sep 06.

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Autor: Goethals O; Tibotec Virco Virology BVBA, Gen De Wittelaan L 11B 3, 2800 Mechelen, Belgium., Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R

Publikováno v: Virology [Virology] 2010 Jul 05; Vol. 402 (2), pp. 338-46. Date of Electronic Publication: 2010 Apr 24.

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Autor: Goethals O; Tibotec BVBA, Mechelen, Belgium. rclayton@its.jnj.com, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K

Publikováno v: Journal of virology [J Virol] 2008 Nov; Vol. 82 (21), pp. 10366-74. Date of Electronic Publication: 2008 Aug 20.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.